Our results above already demonstrated that adjunctive ZOL/IL-2 regimen could enhance immune responses of anti-TB Vγ2Vδ2 T, CD4 + Th1 and CD8 + T effector populations as well as Foxp3+ Tregs. The gene discussed is CD4; the disease is tuberculosis.